Scientists have uncovered a stealthy tactic used by the SARS-CoV-2 virus: one of its proteins can leap from infected cells to ...

Background, cold plasma has some unique properties that enabled it to achieve its desired goals in blood coagulations. However, the coagulation mechanism activated by cold plasma remains elucidated.

Oral anticoagulation (OAC) medicines like warfarin can block clotting proteins and help to prevent blood clots from forming. Warfarin is known to be better than aspirin for people with heart failure ...

Based on these numbers, the researchers estimated that 5-year cumulative risks of recurrent events were 17.4% for ischemic stroke and 22.1% for any stroke overall and 31.2% and 37.5%, respectively, ...

Adults with congenital heart disease are a growing population. One of the major challenges in the care of these patients is to prevent thromboembolic episodes. Despite relative young age and no ...

Heightened interest in left ventricular thrombus (LVT) stems from the consistent association of subsequent stroke and ...

Anticoagulant therapy is the cornerstone of treatment of venous thromboembolism (VTE). Such treatment is divided into 2 stages: Rapid initial anticoagulation is given to minimize the risk of thrombus ...

DOAC classification, mechanism of action, and clinical use DOACs can be classified by their mechanism of action into direct FXa inhibitors (rivaroxaban, apixaban, edoxaban, all including “xa” in the ...

The incidence rates for bleeding events were 3.22 and 2.64 per 100 person-years for the 150 mg and 90 mg doses of abelacimab, respectively, versus 8.38 for rivaroxaban. Notably, gastrointestinal ...

SAN DIEGO & SHANGHAI-- (BUSINESS WIRE)--Sirius Therapeutics today announced promising preliminary data from its Phase 1 first-in-human clinical trial of SRSD107, a next generation siRNA ...

Sirius Therapeutics to Present Data from Its Phase 1 Clinical Trial of Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders at the 66th ASH Annual Meeting and ...